Adaptimmune Therapeutics Plc (ADAP) Exchange: NASDAQ

Adaptimmune Therapeutics is a biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients. The Company’s proprietary platform technologies are designed to utilizing genetic engineering allowing its T-cell product treatments to act as highly specific therapies with enormous potential for treating cancer.Adaptimmune’s platform is founded on the pioneering research of Professor Axel Hoos who in 2000 and 2001 worked as a Visiting Scientist at the Hoffman La Roche labs in Basel, Switzerland. Professor Hoos has been involved in cancer research for nearly 30 years and was one of the first to realize that if T-cells are engineered to target cancer cells, these cells could be used as the ultimate weapon against a tumour – very similar to the body’s natural defence mechanism. Adaptimmune began operations in 2008 with a core strategy of developing T-cell therapies that could be utilized to target cancers. Since then, Adaptimmune has grown significantly. In 2017, they entered a historic collaboration with GlaxoSmithKline, which allowed them to further leverage their individual strengths and accelerate the development of their cancer treatments to positively impact patient lives. Today, Adaptimmune’s clinical development work includes SPEAR T-cells targeting prostate cancer and myeloma, as well as a Phase 1/2 study of an ovarian cancer T-cell therapy. Furthermore, the company is actively engaged in discovery and preclinical development of AnteriXT T-cell therapies for solid tumors, including breast, lung, bladder and prostate cancer as well as other types of cancer including rare tumors.